AMY HULSE: Open Payments
NPI 1396227211 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$649 in 39 payments from 9 companies in 2025. Trend: 2023 $609 · 2024 $782 · 2025 $649
Food & beverage: $649
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $274 |
| GlaxoSmithKline, LLC. | 14 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Viatris Specialty LLC | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $25 |
| United Therapeutics Corporation | 1 | $20 |
| Novartis Pharmaceuticals Corporation | 1 | $16 |
Products named: DUPIXENT, NUCALA, GLASSIA, TRELEGY ELLIPTA, YUPELRI, JASCAYD, Prolastin-C Liquid, OFEV.
Industry payments across KS — which companies pay providers there.
